FDA Finalizes Guidance Documents on Biosimilarity
On Tuesday, and over three years after the initial guidance documents were released, the US Food and Drug Administration released final versions of three guidance documents discussing how FDA will evaluate applications for regulatory approval of biosimilar products:
•Scientific Considerations in Demonstrating Biosimilarity to a Reference Product
•Quality Considerations in Demonstrating…